BAF_FRontier-1In preparation

Study on the Safety and Efficacy of the New Active Ingredient LY4152199 in Patients with Previously Treated B-Cell Lymphoma

Gender
Women and men
Age
18 years and older
Trial type
Interventional
Line of therapy
Relapsed / refractory
Phase
Phase I

What is this trial about?

B-cell are a group of cancers of the . When conventional therapies are no longer effective () or the disease returns (), new treatment options are needed. The goal of the BAF_FRontier-1 study is to investigate the safety, tolerability, and efficacy of the new drug LY4152199. Adults aged 18 and older who have previously been treated for B-cell lymphoma (e.g., diffuse large B-cell lymphoma or ) are eligible to participate in the study.

Trial flow

Requirements

Diagnosis: B-cell lymphoma

Age: 18 years and older

Line of therapy: Rezidiv / primär refraktär

Key inclusion criteria: intolerant to at least two prior lines of therapy; good general condition; no central nervous system (CNS) involvement; no active infection

Allocation

Randomisierung

Treatment

bispecific antibody LY4152199intravenous infusion, first dose escalation than dose optimization, continuation until disease progression

Follow-up

48 months

Detailed description

B-cell lymphomas are a type of . They result from the abnormal growth and proliferation of B-cells, which are a type of white blood cell. These diseases can spread to the lymph nodes, bone marrow, or other organs. The most common forms include diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). usually grows rapidly (high-grade), while FL grows more slowly (low-grade). Initial treatment generally involves chemotherapy combined with . In the event of a relapse or lack of response (refractory), further treatments are necessary.

The goal of this Phase 1 study is to evaluate the LY4152199 in terms of safety, tolerability, and efficacy. It is a so-called that binds to two targets simultaneously. One end binds to the BAFF-R protein on the surface of cancer cells, while the other end binds to of the immune system. By binding to the T cells, the body’s own immune system is intended to be activated to specifically attack and destroy the marked cancer cells. Since this is the first study of this drug in humans (first-in-human), the focus is on determining the appropriate dose and assessing safety. The study consists of two parts, beginning with the so-called phase. In this phase, small groups of patients receive progressively higher doses of the drug to determine the maximum tolerated dose. During the subsequent dose optimization phase, this dose is then further tested in larger groups of patients to confirm the optimal dose for treatment. LY4152199 is administered as an infusion. Patients are closely monitored to detect side effects (e.g., immune system reactions) at an early stage. Treatment continues as long as the cancer does not progress and no serious side effects occur. The of the study is to evaluate the safety and tolerability of LY4152199 in order to determine the maximum tolerated and recommended dose.

Eligible participants are adults aged 18 and older with confirmed B-cell lymphoma who have already received at least two standard therapies and no longer respond to them. Important requirements include adequate function of organs such as the liver, kidneys, and bone marrow, as well as good overall health. Patients with central nervous system involvement or severe active infections are excluded from participation. People with autoimmune diseases or severe cardiovascular diseases, as well as those who have undergone an autologous stem cell transplant (within 100 days), are also ineligible to participate.

Facts

  1. Which disease: B-cell (e.g., , )
  2. Cancer characteristics: previously treated (at least two lines of therapy), recurrent, or
  3. What the study is investigating: Safety, tolerability, and preliminary efficacy of the LY4152199 (BAFF-R x )
  4. Study objective: To determine the optimal dose and assess the
  5. Study duration: Treatment until disease progression, with for up to 4 years
  6. Study characteristics: Phase 1 study (“first-in-human”), open-label (unblinded), and optimization

Trial sites

4 trial sites in Germany are listed.

  • Charité – Universitätsmedizin Berlin

    Berlin

    In preparation
  • Universitätsklinikum Münster

    Albert-Schweitzer-Campus 1, 48149 Muenster

    In preparation
  • LMU Klinikum

    Marchioninistrasse 15, 81377 München

    Status unknown
  • LMU Klinikum Muenchen-Campus Grosshadern

    81377 München

    In preparation

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.